Novavax (NVAX) Competitors

$8.09 +0.06 (+0.77%)

Closing price 03:59 PM Eastern

Extended Trading

$8.21 +0.11 (+1.41%)

As of 07:36 PM Eastern

NVAX vs. MRNA, OCGN, AZN, JNJ, and PFE

Should you be buying Novavax stock or one of its competitors? The main competitors of Novavax include Moderna (MRNA), Ocugen (OCGN), Astrazeneca (AZN), Johnson & Johnson (JNJ), and Pfizer (PFE).

How does Novavax compare to Moderna?

Novavax (NASDAQ:NVAX) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

: Novavax has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Novavax $1.12B 1.18 $440.30M $2.41 3.36
Moderna $2.20B 8.37 -$2.82B -$8.15 N/A
: Novavax has a net margin of 39.19% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Novavax's return on equity.
Company Net Margins Return on Equity Return on Assets
Novavax 39.19% -673.17% 43.53%
Moderna -143.55% -26.64% -19.32%
: Novavax has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500. Comparatively, Moderna has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.
: Novavax presently has a consensus target price of $11.88, suggesting a potential upside of 46.75%. Moderna has a consensus target price of $35.73, suggesting a potential downside of 23.50%. Given Novavax's stronger consensus rating and higher possible upside, equities analysts plainly believe Novavax is more favorable than Moderna.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novavax
3 Sell rating(s)
2 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.20
Moderna
5 Sell rating(s)

12 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
1.84
: 53.0% of Novavax shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 1.0% of Novavax shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
: In the previous week, Moderna had 46 more articles in the media than Novavax. MarketBeat recorded 53 mentions for Moderna and 7 mentions for Novavax. Novavax's average media sentiment score of 0.78 beat Moderna's score of 0.04 indicating that Novavax is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novavax
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Moderna
19 Very Positive mention(s)
4 Positive mention(s)
6 Neutral mention(s)
8 Negative mention(s)
5 Very Negative mention(s)
Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.18	$440.30M	$2.41	3.36
Moderna	$2.20B	8.37	-$2.82B	-$8.15	N/A

Company	Net Margins	Return on Equity	Return on Assets
Novavax	39.19%	-673.17%	43.53%
Moderna	-143.55%	-26.64%	-19.32%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	19 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	8 Negative mention(s)	5 Very Negative mention(s)	Neutral

Summary

Novavax beats Moderna on 10 of the 16 factors compared between the two stocks.

How does Novavax compare to Ocugen?

Ocugen (NASDAQ:OCGN) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

: Novavax has a net margin of 39.19% compared to Ocugen's net margin of -1,192.18%. Novavax's return on equity of -673.17% beat Ocugen's return on equity.
Company Net Margins Return on Equity Return on Assets
Ocugen -1,192.18% -2,626.38% -123.83%
Novavax 39.19% -673.17% 43.53%
: Ocugen currently has a consensus target price of $9.75, suggesting a potential upside of 554.36%. Novavax has a consensus target price of $11.88, suggesting a potential upside of 46.75%. Given Ocugen's stronger consensus rating and higher possible upside, research analysts plainly believe Ocugen is more favorable than Novavax.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocugen
1 Sell rating(s)
0 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.60
Novavax
3 Sell rating(s)

2 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.20
: In the previous week, Ocugen had 11 more articles in the media than Novavax. MarketBeat recorded 18 mentions for Ocugen and 7 mentions for Novavax. Novavax's average media sentiment score of 0.78 beat Ocugen's score of 0.33 indicating that Novavax is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ocugen
3 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Neutral
Novavax
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Novavax has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ocugen $4.41M 114.30 -$67.85M -$0.23 N/A
Novavax $1.12B 1.18 $440.30M $2.41 3.36
: Ocugen has a beta of 2.3, meaning that its share price is 130% more volatile than the S&P 500. Comparatively, Novavax has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500.
: 10.3% of Ocugen shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 4.3% of Ocugen shares are held by company insiders. Comparatively, 1.0% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	-1,192.18%	-2,626.38%	-123.83%
Novavax	39.19%	-673.17%	43.53%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Novavax	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	3 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Novavax	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41M	114.30	-$67.85M	-$0.23	N/A
Novavax	$1.12B	1.18	$440.30M	$2.41	3.36

Summary

Novavax beats Ocugen on 11 of the 16 factors compared between the two stocks.

How does Novavax compare to Astrazeneca?

Astrazeneca (NYSE:AZN) and Novavax (NASDAQ:NVAX) are related companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

: 20.4% of Astrazeneca shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 1.0% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
: Novavax has a net margin of 39.19% compared to Astrazeneca's net margin of 17.19%. Astrazeneca's return on equity of 30.86% beat Novavax's return on equity.
Company Net Margins Return on Equity Return on Assets
Astrazeneca 17.19% 30.86% 12.68%
Novavax 39.19% -673.17% 43.53%
: Astrazeneca has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500. Comparatively, Novavax has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500.
: In the previous week, Astrazeneca had 43 more articles in the media than Novavax. MarketBeat recorded 50 mentions for Astrazeneca and 7 mentions for Novavax. Novavax's average media sentiment score of 0.78 beat Astrazeneca's score of 0.66 indicating that Novavax is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Astrazeneca
20 Very Positive mention(s)
7 Positive mention(s)
11 Neutral mention(s)
3 Negative mention(s)
3 Very Negative mention(s)
Positive
Novavax
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Astrazeneca has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Astrazeneca $58.74B 4.79 $10.23B $5.91 30.69
Novavax $1.12B 1.18 $440.30M $2.41 3.36
: Astrazeneca currently has a consensus target price of $205.33, suggesting a potential upside of 13.22%. Novavax has a consensus target price of $11.88, suggesting a potential upside of 46.75%. Given Novavax's higher possible upside, analysts plainly believe Novavax is more favorable than Astrazeneca.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Astrazeneca
1 Sell rating(s)
0 Hold rating(s)

12 Buy rating(s)

0 Strong Buy rating(s)
2.85
Novavax
3 Sell rating(s)

2 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.20

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.19%	30.86%	12.68%
Novavax	39.19%	-673.17%	43.53%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	20 Very Positive mention(s)	7 Positive mention(s)	11 Neutral mention(s)	3 Negative mention(s)	3 Very Negative mention(s)	Positive
Novavax	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.79	$10.23B	$5.91	30.69
Novavax	$1.12B	1.18	$440.30M	$2.41	3.36

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Novavax	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Astrazeneca beats Novavax on 9 of the 16 factors compared between the two stocks.

How does Novavax compare to Johnson & Johnson?

Johnson & Johnson (NYSE:JNJ) and Novavax (NASDAQ:NVAX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

: 69.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by company insiders. Comparatively, 1.0% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: Novavax has a net margin of 39.19% compared to Johnson & Johnson's net margin of 21.83%. Johnson & Johnson's return on equity of 32.60% beat Novavax's return on equity.
Company Net Margins Return on Equity Return on Assets
Johnson & Johnson 21.83% 32.60% 13.29%
Novavax 39.19% -673.17% 43.53%
: Johnson & Johnson has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Comparatively, Novavax has a beta of 2.37, meaning that its stock price is 137% more volatile than the S&P 500.
: In the previous week, Johnson & Johnson had 67 more articles in the media than Novavax. MarketBeat recorded 74 mentions for Johnson & Johnson and 7 mentions for Novavax. Johnson & Johnson's average media sentiment score of 1.16 beat Novavax's score of 0.78 indicating that Johnson & Johnson is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Johnson & Johnson
54 Very Positive mention(s)
5 Positive mention(s)
9 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Positive
Novavax
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Johnson & Johnson has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Johnson & Johnson $94.19B 5.77 $26.80B $8.65 26.08
Novavax $1.12B 1.18 $440.30M $2.41 3.36
: Johnson & Johnson currently has a consensus target price of $252.48, suggesting a potential upside of 11.92%. Novavax has a consensus target price of $11.88, suggesting a potential upside of 46.75%. Given Novavax's higher probable upside, analysts clearly believe Novavax is more favorable than Johnson & Johnson.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Johnson & Johnson
0 Sell rating(s)
9 Hold rating(s)

18 Buy rating(s)

0 Strong Buy rating(s)
2.67
Novavax
3 Sell rating(s)

2 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.20

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	21.83%	32.60%	13.29%
Novavax	39.19%	-673.17%	43.53%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	54 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive
Novavax	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$94.19B	5.77	$26.80B	$8.65	26.08
Novavax	$1.12B	1.18	$440.30M	$2.41	3.36

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	9 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.67
Novavax	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Johnson & Johnson beats Novavax on 11 of the 16 factors compared between the two stocks.

How does Novavax compare to Pfizer?

Novavax (NASDAQ:NVAX) and Pfizer (NYSE:PFE) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

: 53.0% of Novavax shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 1.0% of Novavax shares are owned by insiders. Comparatively, 0.6% of Pfizer shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
: Novavax presently has a consensus target price of $11.88, suggesting a potential upside of 46.75%. Pfizer has a consensus target price of $28.74, suggesting a potential upside of 8.77%. Given Novavax's higher possible upside, research analysts plainly believe Novavax is more favorable than Pfizer.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novavax
3 Sell rating(s)
2 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.20
Pfizer
3 Sell rating(s)

12 Hold rating(s)

6 Buy rating(s)

1 Strong Buy rating(s)
2.23
: Pfizer has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Novavax $1.12B 1.18 $440.30M $2.41 3.36
Pfizer $62.58B 2.40 $7.77B $1.36 19.43
: Novavax has a net margin of 39.19% compared to Pfizer's net margin of 12.42%. Pfizer's return on equity of 20.48% beat Novavax's return on equity.
Company Net Margins Return on Equity Return on Assets
Novavax 39.19% -673.17% 43.53%
Pfizer 12.42% 20.48% 8.86%
: In the previous week, Pfizer had 89 more articles in the media than Novavax. MarketBeat recorded 96 mentions for Pfizer and 7 mentions for Novavax. Pfizer's average media sentiment score of 0.87 beat Novavax's score of 0.78 indicating that Pfizer is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novavax
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Pfizer
60 Very Positive mention(s)
11 Positive mention(s)
15 Neutral mention(s)
6 Negative mention(s)
1 Very Negative mention(s)
Positive
: Novavax has a beta of 2.37, suggesting that its share price is 137% more volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20
Pfizer	3 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.23

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.18	$440.30M	$2.41	3.36
Pfizer	$62.58B	2.40	$7.77B	$1.36	19.43

Company	Net Margins	Return on Equity	Return on Assets
Novavax	39.19%	-673.17%	43.53%
Pfizer	12.42%	20.48%	8.86%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pfizer	60 Very Positive mention(s)	11 Positive mention(s)	15 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Pfizer beats Novavax on 11 of the 17 factors compared between the two stocks.

Get Novavax News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVAX vs. The Competition

Export

Metric	Novavax	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.33B	$3.40B	$6.25B	$11.87B
Dividend Yield	N/A	2.20%	2.73%	5.21%
P/E Ratio	3.36	38.85	29.04	28.48
Price / Sales	1.18	155.54	476.48	60.89
Price / Cash	2.29	57.88	27.62	36.52
Price / Book	-10.24	7.03	9.67	6.67
Net Income	$440.30M	$23.62M	$3.55B	$332.64M
7 Day Performance	2.17%	3.67%	1.70%	2.01%
1 Month Performance	5.09%	7.17%	5.62%	9.19%
1 Year Performance	29.06%	67.04%	34.42%	39.59%

Novavax Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVAX Novavax	2.6546 of 5 stars	$8.09 +0.8%	$11.88 +46.7%	N/A	$1.33B	$1.12B	3.36	1,990	Upcoming Earnings
MRNA Moderna	1.138 of 5 stars	$48.70 -4.0%	$33.87 -30.5%	N/A	$19.23B	$1.94B	N/A	4,700	Trending News Earnings Report Analyst Forecast Insider Trade Analyst Revision
OCGN Ocugen	1.5725 of 5 stars	$1.70 +2.4%	$9.75 +473.5%	N/A	$557.43M	$4.41M	N/A	80	Trending News Earnings Report Gap Down
AZN Astrazeneca	3.8832 of 5 stars	$187.30 -1.3%	$102.67 -45.2%	N/A	$290.48B	$58.74B	32.27	96,100	Earnings Report Analyst Upgrade
JNJ Johnson & Johnson	4.921 of 5 stars	$225.23 -1.0%	$252.48 +12.1%	N/A	$542.17B	$94.19B	26.04	138,200	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NVAX) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novavax (NVAX) Competitors